The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.

@article{Sullivan2016TheRO,
  title={The role of mitogen-activated protein targeting in melanoma beyond BRAFV600.},
  author={Ryan J. Sullivan},
  journal={Current opinion in oncology},
  year={2016},
  volume={28 2},
  pages={185-91}
}
PURPOSE OF REVIEW Targeted therapy in melanoma is well established for patients with tumors harboring BRAF mutations, but less so for other molecularly defined subsets. In this review, emerging preclinical, genomic, and early clinical data are discussed regarding the use of mitogen-activated protein (MAPK) pathway inhibitors in other molecular subsets of… CONTINUE READING